NetraMark and Juvenescence extend collaboration

Partnership sees AI platform expanded into drug repurposing and discovery.

Canadian AI technology firm NetraMark yesterday announced the extension of its NetraPharma collaboration agreement with Longevity focused life sciences company Juvenescence. NetraPharma is described as a clinical-development focused machine learning initiative and is a 50/50 partnership between the companies.

The companies originally teamed up to use the AI platform for drug resurrection – extracting hidden information from failed or failing clinical trials – but have now expanded the scope of work to include drug repurposing and drug discovery. This announcement highlights a move from psychiatric indications to more focus on Longevity.

Drug repurposing, or indication expansion, is becoming a significant area of research and development, with existing products like aspirin, Metformin and Rapamycin all showing potential as therapies for Longevity related conditions.

Dr Greg Bailey, CEO of Juvenescence, said, “We see this as a novel collaboration to combine NetraMark’s diverse and unique machine learning platform with Juvenescence, as we are positioned as one of the leading drug development companies in the rapidly expanding sector focused on developing therapies to modify aging.”

NetraPharma uses a novel mathematical technique to integrate the outputs of multiple different machine learning algorithms, including gradient boosting, random forests, neural networks, GANs, quantum computation, and others. It enables the segmentation of subgroups within datasets when only a limited number of inputs are available. The system is claimed to be particularly adept at identifying placebo responders and non-responders, and with patient reported outcome measures (PROMs).

Dr Joseph Geraci, CEO of Toronto-based NetraMark, said, “After years of development and validation by the NetraMark tech team, the NetraAI machine learning suite is providing us with valuable insights into aging. The result is a very exciting collaboration with Juvenescence, one of the premier biotech companies focusing on modifying aging.”

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Latest articles

COVID-19: Leading clinician calls for focus on the biology of aging

Dr Nir Barzilai predicts that rapamycin could decrease severity of coronavirus in the elderly by 50%. When it comes to the world of Longevity and...

Global investment consortium slated to back Telocyte into Phase 1

Telomerase therapy ready for human Alzheimer’s trials. “There have been more than 400 registered trials for Alzheimer's and, by global consensus, every single one has...

Longevity 2020: shaping-up nicely

Over 45 confirmed speakers for this 5-day online event and a big thank you for your interest. We're moving fast! Longevity 2020 started just over...

Telomeres on repeat to inhibit inflamm-aging

Coming around again – Italian team hopes to use repeated nucleobases to delay aging through extending telomeres. Inflammation is a double-edged sword; while it is necessary...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.